Markers of Immune Stimulation in the Cerebrospinal Fluid During HIV Infection: A longitudinal study

Abstract

Markers of immune stimulation were studied in 76 sequential cerebrospinal fluid (CSF) samples from 19 patients infected with HIV-1 without antiretroviral treatment during observation periods ranging from 22 months to 6 years. Eight of these patients were further followed with 14 CSF samples for 3–24 months of zidovudine treatment. During the course of HIV-1 infection, the mean CSF neopterin and β₂-microglobulin (β2M) concentrations increased from 12.7 to 20.4 nmol/l (p < 0.01) and from 1.93 to 2.17 mg/l (p < 0.05), respectively, while the mean peripheral CD4 + T cell count decreased from 624 to 320 cells × 10⁶/l (p < 0.001). The IgG index, reflecting intrathecal immunoglobulin production, increased from 0.72 to 0.92 (p = 0.08). The number of patients with CSF pleocytosis did not change significantly during follow-up (8/19 at baseline, 7/19 at endpoint). In the 8 patients followed up during antiretroviral treatment, a significant reduction in mean CSF levels of neopterin and β2M (-48% and-32%, respectively, p < 0.01) was seen after 3–12 months on zidovudine. We suggest that a gradual increase in immune stimulation reflected by the rising CSF concentrations of neopterin and β2M indicates that HIV-1 infection in the central nervous system is progressive even in neurologically asymptomatic stages.